Ocular allergy/inflammation:

Indications for: ALREX

Seasonal allergic conjunctivitis.

Clinical Trials:

In two double-masked, placebo-controlled six-week environmental studies of 268 patients with seasonal allergic conjunctivitis, Alrex, when dosed 4 times per day was superior to placebo in the treatment of the signs and symptoms of seasonal allergic conjunctivitis. Alrex reduced bulbar conjunctival injection and itching, beginning approximately 2 hours after instillation of the first dose and throughout the first 14 days of treatment.

Adult Dosage:

1 drop into affected eye(s) 4 times daily.

Children Dosage:

Not recommended.

ALREX Contraindications:

Ocular fungal, viral, or mycobacterial infections.

ALREX Warnings/Precautions:

Reevaluate if no improvement after 2 days. Prescribe initially and renew after 14 days only after appropriate exam. Corneal or scleral thinning. Glaucoma. History of herpes simplex. Monitor IOP and for secondary infections in prolonged therapy (>10 days). Avoid abrupt cessation. Soft contact lenses (remove, may reinsert 10 minutes after instillation). Pregnancy (Cat.C). Nursing mothers.

ALREX Classification:


Adverse Reactions:

Local reactions (eg, blurred vision, burning, itching, dry eye), photophobia, headache, rhinitis, pharyngitis. May mask or exacerbate ocular infections. Prolonged use may increase: IOP, optic nerve damage, visual acuity and field defects, cataract formation, corneal perforation.


Hepatic. ~98% serum protein bound.

Drug Elimination:


How Supplied:

Susp—5mL, 10mL